205 related articles for article (PubMed ID: 38498726)
41. Molecular Weights of Bovine and Porcine Heparin Samples: Comparison of Chromatographic Methods and Results of a Collaborative Survey.
Bertini S; Risi G; Guerrini M; Carrick K; Szajek AY; Mulloy B
Molecules; 2017 Jul; 22(7):. PubMed ID: 28753946
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.
Crowther MA; Berry LR; Monagle PT; Chan AK
Br J Haematol; 2002 Jan; 116(1):178-86. PubMed ID: 11841415
[TBL] [Abstract][Full Text] [Related]
43. Preparation and evaluation a new generation of low molecular weight heparin.
Zhao D; Sang Q; Cui H
Biomed Pharmacother; 2016 Apr; 79():194-200. PubMed ID: 27044828
[TBL] [Abstract][Full Text] [Related]
44. Chemometric analysis of porcine, bovine and ovine heparins.
Ouyang Y; Han X; Yu Y; Chen J; Fu L; Zhang F; Linhardt RJ; Fareed J; Hoppensteadt D; Jeske W; Kouta A; Zhang Z; Xia K
J Pharm Biomed Anal; 2019 Feb; 164():345-352. PubMed ID: 30428408
[TBL] [Abstract][Full Text] [Related]
45. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
[TBL] [Abstract][Full Text] [Related]
46. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
[TBL] [Abstract][Full Text] [Related]
47. New developments in quantitative polymerase chain reaction applied to control the quality of heparins.
Auguste C; Dereux S; Martinez C; Anger P
Anal Bioanal Chem; 2011 Jan; 399(2):747-55. PubMed ID: 20931175
[TBL] [Abstract][Full Text] [Related]
48. Novel method for the determination of average molecular weight of natural polymers based on 2D DOSY NMR and chemometrics: Example of heparin.
Monakhova YB; Diehl BWK; Do TX; Schulze M; Witzleben S
J Pharm Biomed Anal; 2018 Feb; 149():128-132. PubMed ID: 29112901
[TBL] [Abstract][Full Text] [Related]
49. Quantitative PCR and disaccharide profiling to characterize the animal origin of low-molecular-weight heparins.
Houiste C; Auguste C; Macrez C; Dereux S; Derouet A; Anger P
Clin Appl Thromb Hemost; 2009 Feb; 15(1):50-8. PubMed ID: 18805847
[TBL] [Abstract][Full Text] [Related]
50. Quantitative Analysis of Impurities in Unfractionated Heparin of Bovine Origin.
Workman WE; Carrick KL
Front Med (Lausanne); 2019; 6():315. PubMed ID: 31998734
[TBL] [Abstract][Full Text] [Related]
51. In vitro and in vivo characterization of a reversible synthetic heparin analog.
Whelihan MF; Cooley B; Xu Y; Pawlinski R; Liu J; Key NS
Thromb Res; 2016 Feb; 138():121-129. PubMed ID: 26709038
[TBL] [Abstract][Full Text] [Related]
52. Advancements in heparosan production through metabolic engineering and improved fermentation.
Sheng LL; Cai YM; Li Y; Huang SL; Sheng JZ
Carbohydr Polym; 2024 May; 331():121881. PubMed ID: 38388039
[TBL] [Abstract][Full Text] [Related]
53. Bioengineered heparins and heparan sulfates.
Fu L; Suflita M; Linhardt RJ
Adv Drug Deliv Rev; 2016 Feb; 97():237-49. PubMed ID: 26555370
[TBL] [Abstract][Full Text] [Related]
54. Non-Anticoagulant Low Molecular Weight Heparins for Pharmaceutical Applications.
Ouyang Y; Yu Y; Zhang F; Chen J; Han X; Xia K; Yao Y; Zhang Z; Linhardt RJ
J Med Chem; 2019 Jan; 62(2):1067-1073. PubMed ID: 30608147
[TBL] [Abstract][Full Text] [Related]
55. Development of hydrophilic interaction chromatography with quadruple time-of-flight mass spectrometry for heparin and low molecular weight heparin disaccharide analysis.
Ouyang Y; Wu C; Sun X; Liu J; Linhardt RJ; Zhang Z
Rapid Commun Mass Spectrom; 2016 Jan; 30(2):277-84. PubMed ID: 26689158
[TBL] [Abstract][Full Text] [Related]
56. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
Lin P; Sinha U; Betz A
Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
[TBL] [Abstract][Full Text] [Related]
57. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
[TBL] [Abstract][Full Text] [Related]
58. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
59. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
60. Movement of heparins across rat gastric mucosa is dependent on molecular weight and pH.
Moazed B; Hiebert LM
Pharm Res; 2009 Jan; 26(1):189-95. PubMed ID: 18937058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
